A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Who May Qualify: 1. Participants with Progressive forms of Multiple Sclerosis including Primary Progressive and Secondary Progressive MS. 2. Participants must have discontinued disease modifying therapy (DMT) prior to signing the ICF and meet the following washout criteria prior to receiving lymphodepletion. Who Should NOT Join This Trial: 1. History of malignancy that has not been in remission for at least 2 years. 2. Viral Screening 1. Evidence of chronic active or history of hepatitis B virus (HBV). 2. Seropositive for human weakened immune system virus (HIV) antibody. 3. History of bone marrow/hematopoietic stem cell or solid organ transplantation. 4. Prior treatment with adoptive T-cell therapy or any gene therapy product directed at any target (e.g. CAR T-cell therapy). Note: Other protocol-specified Inclusion/Exclusion criteria may apply. Always talk to your doctor about whether this trial is right for you.